nalidixic acid
Trade name: neggram
Approved
Mar 6, 1964
Nalidixic acid is a quinolone antibacterial indicated for the treatment of urinary tract infections. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are generally resistant to the drug. It is suggested that nalidixic acid acts by inhibiting bacterial DNA gyrase. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 3 marketing orgs
Timeline
1960s
- Mar 6, 1964
Sanofi-Aventis — Earliest FDA Approval
- Mar 6, 1964
Sanofi-Aventis — NDA Organization
- Mar 6, 1964
Sanofi-Aventis — NDA Secondary Org
1980s
- Mar 28, 1986
Sun Pharmaceuticals — Marketing Organization
- Jun 28, 1988
Watson Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- Bacterial DNA gyraseANTAGONIST
Bacterial DNA gyrase antagonist
Approval history
- approvedPriority reviewMar 6, 1964
Chemistry & pharmacology
SMILES
CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2- Mol. weight
- 232.2353 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNalidixic acid ↗
- NCATS3B91HWA56M ↗
- ChEMBLCHEMBL5 ↗
- ChEMBLCHEMBL3707258 ↗
Also known as
- 1,4-dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
- 1,4-dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
- 1-aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
- 1-aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
- 1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
- 1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
- 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid
- 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid
- 1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
- 1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
- 3-carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
- 3-carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
- acide nalidixique
- acide nalidixique
- acido nalidixico
- acido nalidixico
- acidum nalidixicum
- acidum nalidixicum
- nalidic acid
- nalidixane
- nalidixane
- nalidixate
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid
- nalidixic acid citrated
- nalidixic acid sodium
- nalidixic acid sodium salt
- nalidixinic acid
- nalidixinsäure
- nalidixinsäure
- nalix
- nalix
- neggram
- neggram
- neggram
- neg gram
- negram
- negram
- uriben
- uriben
- uroneg
- uroneg
- win-18320
- win-18320
- wintomylon
- wintomylon
Organizations
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Sanofi-Aventis | For profit | NDA | Mar 6, 1964 |
| Sanofi-Aventis | For profit | NDA2 | Mar 6, 1964 |
| Sun Pharmaceuticals | For profit | MKTG | Mar 28, 1986 |
| Watson Pharmaceuticals | For profit | MKTG | Jun 28, 1988 |